Bibliography
- Caudy AA, Myers M, Hannon GJ, Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev 2002;16:2491-6
- Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15:188-200
- Grimm D. Small silencing RNAs: state-of-the-art. Adv Drug Deliv Rev 2009;61:672-703
- Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009;61:850-62
- Zhang EE, Liu AC, Hirota T, A genome-wide RNAi screen for modifiers of the circadian clock in human cells. Cell 2009;139:199-210
- Lee AJ, Kolesnick R, Swanton C. RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance. Expert Rev Mol Med 2009;11:e15
- Lage H. Therapeutic potential of RNA interference in drug-resistant cancers. Future Oncol 2009;5:169-85
- McManus MT, Haines BB, Dillon CP, Small interfering RNA-mediated gene silencing in T lymphocytes. J Immunol 2002;169:5754-60
- Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007;8:173-84
- Bumcrot D, Manoharan M, Koteliansky V, RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006;2:711-9
- Aigner A. Cellular delivery in vivo of siRNA-based therapeutics. Curr Pharm Des 2008;14:3603-19
- Donze O, Picard D. RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res 2002;30:e46
- Burger PC, Vogel FS, Green SB, Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985;56:1106-11
- Jellinger K. Glioblastoma multiforme: morphology and biology. Acta Neurochir (Wien) 1978;42:5-32
- Singh SK, Clarke ID, Terasaki M, Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8
- Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 1987;59:1617-25
- Sathornsumetee S, Rich JN. Designer therapies for glioblastoma multiforme. Ann NY Acad Sci 2008;1142:108-32
- Stupp R, Mason WP, van den Bent MJ, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
- Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 2005;25:1-7
- Kondo Y, Hollingsworth EF, Kondo S. Molecular targeting for malignant gliomas [review]. Int J Oncol 2004;24:1101-9
- Kanu OO, Hughes B, Di C, Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol 2009;3:39-52
- Sathornsumetee S, Reardon DA. Targeting multiple kinases in glioblastoma multiforme. Expert Opin Investig Drugs 2009;18:277-92
- Chang SM, Butowski NA, Sneed PK, Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme. Neurosurg Focus 2006;20:E4
- Mathupala SP, Guthikonda M, Sloan AE. RNAi based approaches to the treatment of malignant glioma. Technol Cancer Res Treat 2006;5:261-9
- Wyszko E, Rolle K, Nowak S, A multivariate analysis of patients with brain tumors treated with ATN-RNA. Acta Pol Pharm 2008;65:677-84
- Zukiel R, Nowak S, Wyszko E, Suppression of human brain tumor with interference RNA specific for tenascin-C. Cancer Biol Ther 2006;5:1002-7
- Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990;2:279-89
- Fire A, Xu S, Montgomery MK, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11
- Elbashir SM, Harborth J, Lendeckel W, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8
- Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 2003;9:1034-48
- Chua JH, Armugam A, Jeyaseelan K. MicroRNAs: biogenesis, function and applications. Curr Opin Mol Ther 2009;11:189-99
- Tabara H, Yigit E, Siomi H, The dsRNA binding protein RDE-4 interacts with RDE-1, DCR-1, and a DExH-box helicase to direct RNAi in C. elegans. Cell 2002;109:861-71
- Martinez J, Patkaniowska A, Urlaub H, Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002;110:563-74
- Hamada M, Ohtsuka T, Kawaida R, Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev 2002;12:301-9
- Hammond SM, Boettcher S, Caudy AA, Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 2001;293:1146-50
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97
- Lee Y, Ahn C, Han J, The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425:415-9
- Lund E, Guttinger S, Calado A, Nuclear export of microRNA precursors. Science 2004;303:95-8
- Bernstein E, Caudy AA, Hammond SM, Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409:363-6
- Schwarz DS, Hutvagner G, Du T, Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003;115:199-208
- Pushparaj PN, Aarthi JJ, Kumar SD, RNAi and RNAa–The Yin and Yang of RNAome. Bioinformation 2008;2:235-7
- Shrey K, Suchit A, Nishant M, RNA interference: emerging diagnostics and therapeutics tool. Biochem Biophys Res Commun 2009;386:273-7
- Sah DW. Therapeutic potential of RNA interference for neurological disorders. Life Sci 2006;79:1773-80
- Rao DD, Vorhies JS, Senzer N, siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009;61:746-59
- John M, Constien R, Akinc A, Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 2007;449:745-7
- Abbas-Terki T, Blanco-Bose W, Deglon N, Lentiviral-mediated RNA interference. Hum Gene Ther 2002;13:2197-201
- Xia XG, Zhou H, Ding H, An enhanced U6 promoter for synthesis of short hairpin RNA. Nucleic Acids Res 2003;31:e100
- Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002;9:1327-33
- Boudreau RL, Martins I, Davidson BL. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 2009;17:169-75
- Olivier A, Jeanson-Leh L, Bouma G, A partial down-regulation of WASP is sufficient to inhibit podosome formation in dendritic cells. Mol Ther 2006;13:729-37
- McBride JL, Boudreau RL, Harper SQ, Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008;105:5868-73
- Mathupala SP. Delivery of small-interfering RNA (siRNA) to the brain. Expert Opin Ther Pat 2009;19:137-40
- Pardridge WM. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther 2004;4:1103-13
- Bartlett DW, Davis ME. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng 2007;97:909-21
- Hannon GJ, Conklin DS. RNA interference by short hairpin RNAs expressed in vertebrate cells. Methods Mol Biol 2004;257:255-66
- Zhang Y, Zhang YF, Bryant J, Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004;10:3667-77
- Grzelinski M, Urban-Klein B, Martens T, RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006;17:751-66
- Li L, Yang L, Scudiero DA, Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells. Gene Ther 2007;14(10):814-27
- Markert JM, Gillespie GY, Weichselbaum RR, Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 2000;10:17-30
- Oehmig A, Fraefel C, Breakefield XO. Update on herpesvirus amplicon vectors. Mol Ther 2004;10:630-43
- Saydam O, Glauser DL, Heid I, Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol Ther 2005;12:803-12
- Saydam O, Saydam N, Glauser DL, HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation. Gene Ther 2007;14:1143-51
- Manjunath N, Wu H, Subramanya S, Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev 2009;61:732-45
- Kock N, Kasmieh R, Weissleder R, Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 2007;9:435-42
- Konnikova L, Kotecki M, Kruger MM, Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 2003;3:23
- Jackson AL, Burchard J, Schelter J, Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 2006;12:1179-87
- Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008;19:111-24
- Judge AD, Sood V, Shaw JR, Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457-62
- Hornung V, Guenthner-Biller M, Bourquin C, Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11:263-70
- Grimm D, Streetz KL, Jopling CL, Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-41
- Chamberlain MC. Antiangiogenic blockage: a new treatment for glioblastoma. Expert Opin Biol Ther 2008;8:1449-53